174 related articles for article (PubMed ID: 22838644)
1. Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer.
Ishikawa T; Kokura S; Sakamoto N; Ando T; Imamoto E; Hattori T; Oyamada H; Yoshinami N; Sakamoto M; Kitagawa K; Okumura Y; Yoshida N; Kamada K; Katada K; Uchiyama K; Handa O; Takagi T; Yasuda H; Sakagami J; Konishi H; Yagi N; Naito Y; Yoshikawa T
Int J Hyperthermia; 2012; 28(7):597-604. PubMed ID: 22838644
[TBL] [Abstract][Full Text] [Related]
2. Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial.
Davis JL; Pandalai P; Ripley RT; Langan RC; Steinberg SM; Walker M; Toomey MA; Levy E; Avital I
Trials; 2011 May; 12():129. PubMed ID: 21595953
[TBL] [Abstract][Full Text] [Related]
3. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
Girard N; Mornex F; Bossard N; Ychou M; Chauffert B; Wautot V
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1426-32. PubMed ID: 20056351
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
Ishii H; Furuse J; Boku N; Okusaka T; Ikeda M; Ohkawa S; Fukutomi A; Hamamoto Y; Nakamura K; Fukuda H;
Jpn J Clin Oncol; 2010 Jun; 40(6):573-9. PubMed ID: 20185458
[TBL] [Abstract][Full Text] [Related]
5. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Ikeda M; Okada S; Tokuuye K; Ueno H; Okusaka T
Br J Cancer; 2002 May; 86(10):1551-4. PubMed ID: 12085203
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer.
Furuse J; Ishii H; Okusaka T; Nagase M; Nakachi K; Ueno H; Ikeda M; Morizane C; Yoshino M
Jpn J Clin Oncol; 2005 Dec; 35(12):733-8. PubMed ID: 16303793
[TBL] [Abstract][Full Text] [Related]
8. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer.
Tschoep-Lechner KE; Milani V; Berger F; Dieterle N; Abdel-Rahman S; Salat C; Issels RD
Int J Hyperthermia; 2013; 29(1):8-16. PubMed ID: 23245336
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
Mamon HJ; Niedzwiecki D; Hollis D; Tan BR; Mayer RJ; Tepper JE; Goldberg RM; Blackstock AW; Fuchs CS;
Cancer; 2011 Jun; 117(12):2620-8. PubMed ID: 21656739
[TBL] [Abstract][Full Text] [Related]
11. Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer.
Zhao H; Yang G; Wang D; Yu X; Zhang Y; Zhu J; Ji Y; Zhong B; Zhao W; Yang Z; Aziz F
Anticancer Drugs; 2010 Apr; 21(4):447-52. PubMed ID: 20075714
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and factors affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced pancreatic cancer.
Huang PI; Chao Y; Li CP; Lee RC; Chi KH; Shiau CY; Wang LW; Yen SH
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):159-65. PubMed ID: 18508203
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
Ko AH; Quivey JM; Venook AP; Bergsland EK; Dito E; Schillinger B; Tempero MA
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):809-16. PubMed ID: 17363191
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer.
de Lange SM; van Groeningen CJ; Meijer OW; Cuesta MA; Langendijk JA; van Riel JM; Pinedo HM; Peters GJ; Meijer S; Slotman BJ; Giaccone G
Eur J Cancer; 2002 Jun; 38(9):1212-7. PubMed ID: 12044508
[TBL] [Abstract][Full Text] [Related]
15. Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study.
Beane JD; Griffin KF; Levy EB; Pandalai P; Wood B; Abi-Jaoudeh N; Beresnev T; Shutack Y; Webb CC; Avital I; Rudloff U
Invest New Drugs; 2015 Feb; 33(1):109-18. PubMed ID: 25236592
[TBL] [Abstract][Full Text] [Related]
16. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2.
Nakai Y; Isayama H; Ijichi H; Sasaki T; Takahara N; Ito Y; Matsubara S; Uchino R; Yagioka H; Arizumi T; Hamada T; Miyabayashi K; Mizuno S; Yamamoto K; Kogure H; Yamamoto N; Hirano K; Sasahira N; Tateishi K; Tada M; Koike K
Invest New Drugs; 2013 Oct; 31(5):1294-9. PubMed ID: 23690239
[TBL] [Abstract][Full Text] [Related]
17. Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer.
Shinoto M; Yamada S; Terashima K; Yasuda S; Shioyama Y; Honda H; Kamada T; Tsujii H; Saisho H;
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):498-504. PubMed ID: 26883565
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Uesaka K; Boku N; Fukutomi A; Okamura Y; Konishi M; Matsumoto I; Kaneoka Y; Shimizu Y; Nakamori S; Sakamoto H; Morinaga S; Kainuma O; Imai K; Sata N; Hishinuma S; Ojima H; Yamaguchi R; Hirano S; Sudo T; Ohashi Y;
Lancet; 2016 Jul; 388(10041):248-57. PubMed ID: 27265347
[TBL] [Abstract][Full Text] [Related]
20. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.
Mitry E; Hammel P; Deplanque G; Mornex F; Levy P; Seitz JF; Moussy A; Kinet JP; Hermine O; Rougier P; Raymond E
Cancer Chemother Pharmacol; 2010 Jul; 66(2):395-403. PubMed ID: 20364428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
